Ceftazidime: therapeutic results in various infections and kinetic studies

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Microbiology

Background:

• Severe bacterial infections pose significant treatment challenges, often involving multidrug-resistant pathogens.
• Previous antibiotic therapies had failed in many of the studied patients.
• Pyelonephritis and lower respiratory tract infections were common indications.

Purpose of the Study:

• To evaluate the efficacy and safety of ceftazidime in treating serious bacterial infections.
• To assess ceftazidime's pharmacokinetic profile, including serum, urine, and bone levels.
• To determine appropriate dosing for various infection types.

Main Methods:

• A cohort of 45 patients with acute or recurrent pyelonephritis, lower respiratory infection, or other serious infections received ceftazidime.
• Dosage ranged from 1 to 6 g daily, administered intramuscularly or intravenously.
• Bacteriological assessments and clinical outcomes were monitored. Pharmacokinetic parameters were measured.

Main Results:

• All patients achieved clinical cure or improvement, with organism eradication in 35 out of 45 patients.
• Ceftazidime demonstrated excellent tolerance, with only minor transient adverse effects reported.
• High serum, urine, and bone levels were achieved, with an average half-life of 2.6 hours.

Conclusions:

• Ceftazidime is a safe and effective antibiotic for treating serious bacterial infections, including those caused by multidrug-resistant bacteria.
• Specific dosing recommendations were established: 0.5 g every 12 hours for urinary infections, with higher doses for other infections, particularly those involving Pseudomonas aeruginosa.
• The pharmacokinetic data support the observed clinical efficacy.